Sarah Aiosa – SVP & President Latin America, MSD
Sarah Aiosa, SVP and President of MSD (known as Merck & Co. in the U.S. and Canada) for Latin America, highlights nearly four years of strong growth built on a…
Regenerative medicine aims to replace or regenerate damaged cells, tissues, or organs, both structurally and functionally, which have lost their optimal biological regulatory condition. Regeneration in nature can occur at the cellular, tissue, organ, structural, and even whole body levels, but in humans is naturally significantly limited with aging.
To achieve a transformational level of technological advancement in this area for humans, RegenerAge is utilizing novel combination applications of biological interventions, including stem cells, soluble regenerative biologics, proprietary nutritional bio-products, functional and regenerative based diets, bioidentical hormone replacement, and skin / aesthetic rejuvenation tools, yielding an unprecedented, integrated option for activating the natural healing processes of the body and maintaining health and wellness.
Regenerative medicine incorporates various fields of science, including genetics, biomedical engineering, tissue engineering, advanced cell technology, and evolutionary dynamics, with the goal of allowing human bodies to recover cellular function, vitality and optimizing its integrated operation.
Smart prevention is the best initial approach for any disease, but once an illness manifests as part of a person’s life, regeneration and repair are invaluable options to restore health and restructure damaged tissues and cells within the human body. Recent biotechnology related advances present wonderful opportunities for RegenerAge to improve outcomes when patients need more than traditional treatments, as well as to increase lifespan and wellness for those conscious about their health and longevity.
RegenerAge is open to working with all types of patients according to their medical status. Our treatments may help patients who suffer from a variety of chronic degenerative diseases including, but not limited to: cardiovascular conditions, diabetes, kidney damage, different types of cancer, auto-immune diseases, CNS degeneration, and hematological disorders.
Contact
Address: BNY Mellon Center 1735 Market Street, Suite 3750 Philadelphia PA 19103 USA
Tel. +52 55 3028 4783
Website: https://regenerage.clinic/es/
Sarah Aiosa, SVP and President of MSD (known as Merck & Co. in the U.S. and Canada) for Latin America, highlights nearly four years of strong growth built on a…
Pharmaceutical innovators are sounding the alarm on Mexico’s healthcare reforms, despite the government’s bold claims. At industry group AMIIF’s 75th anniversary, Health Secretary David Kershenobich hailed the Sheinbaum administration’s investments…
In her latest strategy to tackle Mexico’s persistent medicine shortages – a struggle inherited from predecessor López Obrador – President Claudia Sheinbaum has issued a decree that seeks to attract…
Mexico has a long history of public healthcare reforms that have fluctuated along with the changing tides of the country’s government. The latest is an ambitious plan for the Institute…
Rare diseases, by definition, only affect small patient populations. However, when the more than 7,000 known rare conditions are taken together, their impact is enormous. Rare disease patients, for example,…
Whenever the international investor community contemplates doing business in Mexico’s life science sector, the primary appeal usually derives from the sheer size of the marketplace and its underlying growth potential…
Mexico has firmly established itself as a regional powerhouse in medical device manufacturing. The country is home to the second-largest medtech market in Latin America, employs around 160,000 people in…
Valued at USD 7.28 billion, the Mexican pharma market stands out within Latin America, ranking second only to Brazil, and registering a solid compound annual growth rate of six percent…
In recent decades, Mexico has gained notoriety as one of the countries most heavily afflicted by the global epidemic of obesity. Ranking second only to the United States in terms…
Mexico has long been considered a relatively appealing destination for clinical trials and, in recent years, has participated in more than one percent of global drug development research, generating an…
This interview explores Esmeralda Ortiz’s transformative leadership at Grupo Loeffler Russek (GLR), where she has worked to professionalize operations, strengthen the product portfolio, and position the company for sustainable growth.…
Karla Alcazar, Head of LATAM at Eli Lilly, discusses the company’s plans to tackle pressing regional health challenges such as obesity, diabetes, and cancer, while also highlighting the region’s critical…
See our Cookie Privacy Policy Here
